6533b7d2fe1ef96bd125e1c6
RESEARCH PRODUCT
Mitral valve therapy still surgical?
Giuseppe SpezialeMaria Cristina BarattoniGiuseppe NassoAngelo SqueriFrancesco GuccioneKhalil FattouchPietro DioguardiP. RussoGiuseppe VadalàFausto Castriotasubject
medicine.medical_specialtyMitral valve repairMitral regurgitationPercutaneousbusiness.industryClinical outcomemedicine.medical_treatmentStandard treatmentMitraClipNew devicevalvular heart diseasemedicine.diseasemedicine.anatomical_structureAortic valve stenosisInternal medicineMitral valvecardiovascular systemmedicineCardiologyTranscatheter mitral valve therapybusinessCardiology and Cardiovascular MedicineMitral valve repairLong-term repair resultdescription
Mitral regurgitation (MR) is the second most common valvular heart disease after aortic valve stenosis. With increased understanding of the heterogenic pathophysiology of MR, cardiac surgeons have developed various techniques that increase the likelihood of successful mitral valve repair (MVR). Nowadays, a rate of repair >90% may be reached in some mitral valve reference centres. In recent years, the introduction of transcatheter mitral valve intervention techniques has opened up new frontiers in mitral therapy, specifically in patients at high risk for standard surgery. Current percutaneous technologies for MVR have been developed on the basis of some of the surgical principles. Based on current evidence, surgery remains the standard treatment for MR according to very long-term survival and durability of MVR using Carpentier's technique. Today, in clinical practice, only the MitraClip device may be considered as a real and effective alternative in selected patients with high or prohibitive risk for surgery.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-03-01 |